DNA Polymerase Market to exhibit a CAGR of approximately 6.5% during the forecast period by 2031

A growing number of drug patent expirations and the interest in generic biologics has gained significantly from developments in the DNA polymerase market. Rising demand for improvements in healthcare diagnostics are expected to remain key influencer in market growth. According to Future Market Insights, a new study has forecast the DNA polymerase market to exhibit a CAGR of approximately 6.5% during the forecast period from 2021 to 2031.

Major manufacturers in the DNA polymerase market are increasingly focused on investing in research and development efforts to widen the scope of applications in the sector. In addition, strategic acquisitions and collaborations to share expertise, leveraging biopharmaceuticals and contract manufacturing companies will find ground in the industry.

In terms of end users, molecular diagnostics companies are likely to remain primary contributors to the market accounting for more than 30% of the global market share. Furthermore, academic and research institutes will display a relatively faster rate of growth, driven by investments into R&D for accuracy in diagnostics, genome research, DNA cloning, and potential applications in cancer research.

Increasing R&D activities is a key factor positively influencing the development and use of high-fidelity DNA polymerase. Increasing incidences of cancer, concerns over uncontrolled genetic mutations, increasing awareness on neurological disorders, and potential for treating chronic diseases create lucrative opportunities in the DNA polymerase market. Also, the growing importance being given to personalized medicine will provide impetus to market players through the coming decade.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-801 

On the other hand, DNA polymerase market players are expected to face a number of challenges during the forecast period. For instance, shortage of adequately skilled professionals is a restraining factor affecting the market. Lack of information and awareness associated to DNA polymerase also affects sales prospects. Also, a shortage of funding by governments in the sector are restraining market growth. These factors are especially true in developing countries with restricted access to capital and infrastructure.

Key Takeaways from DNA Polymerase Market Study

• The global DNA polymerase market is projected to grow at approximately 6.5% CAGR through the projection period.
• Molecular diagnostic applications will account for major market, with impetus from the covid-19 pandemic.
• The U.S. will hold the lead in North America accounting for more than 50% of the global valuation.
• China will reflect high growth potential accounting for a CAGR of over 7.5%, owing to rising healthcare spending.
• UK will reflect high demand in Europe supported by the rise of contract research and manufacturing organizations in biopharmaceuticals.

“The introduction of numerous government initiatives and rising levels of government funding efforts for R&D activities, are key factors that are expected to bolster the growth of high-fidelity DNA polymerase offerings. Furthermore, the increasing occurrence of genetic disease, is also one of the major factors supporting growth in the market through the assessment period,” said an FMI analyst.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-801

Who is Winning?

The global DNA polymerase market is set to widen its scope of expansion through the assessment period, driven by a higher rate of adoption in molecular diagnostics, bioprocessing, cancer research and development of generic biologics in the biopharmaceutical sector. A shortage of adequately skilled professionals and lack of awareness has restrained revenue in the industry.

Some of the more prominent players in the DNA polymerase market include but are not limited to Thermo Fisher Scientific Inc., Hoffmann-La Roche AG, Merck KGaA, Qiagen N.V., Agilent Technologies Inc., Takara Bio Inc., Genescript, Illumina Inc., New England Biolabs, Inc., Bioline, and Promega Corporation.

Key Segments

Product Type

• Prokaryotic DNA polymerase
• Eukaryotic DNA polymerase

End Use

• Molecular diagnostics companies
• Diagnostic laboratories
• Academic and research institutes
• Biopharmaceutical companies
• Hospitals

For critical insights on this market, request to ask an expert here @ https://www.futuremarketinsights.com/askus/rep-gb-801 

Region

• North America (U.S. & Canada)
• Latin America (Mexico, Brazil, Argentina, Chile, Peru, & Rest of LATAM)
• Western Europe (Germany, U.K., France, Italy, Spain, BENELUX, Nordic, & Rest of W. Europe)
• Eastern Europe (Russia, Poland, CIS Countries and Rest of E. Europe)
• Middle East and Africa (GCC Countries, Turkey, South Africa, Israel, & Rest of MEA)
• Japan
• Asia Pacific excluding Japan (China, India, ASEAN, South Korea, Australia, & Rest of APEJ)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs